Cogent Biosciences (COGT) Total Liabilities (2017 - 2026)

Cogent Biosciences (COGT) has reported Total Liabilities for 10 consecutive years, with $295.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Liabilities rose 355.71% year-over-year to $295.3 million; the TTM figure through Mar 2026 stood at $295.3 million (up 355.71% YoY), while the FY2025 annual figure was $301.2 million, up 320.65% from the prior year.
• Total Liabilities retreated to $295.3 million in Q1 2026 per COGT's latest filing, from $301.2 million in the prior quarter.
• Across five years, Total Liabilities topped out at $301.2 million in Q4 2025 and bottomed at $19.0 million in Q1 2022.
• Historically, Total Liabilities has averaged $88.2 million across 5 years, with a median of $55.6 million in 2023.
• Annual changes were most pronounced in 2023 — Total Liabilities decreased 5.84% — and 2026, when it surged 355.71%.
• Cogent Biosciences' Total Liabilities stood at $45.1 million in 2022, then climbed by 23.43% to $55.6 million in 2023, then climbed by 28.72% to $71.6 million in 2024, then surged by 320.65% to $301.2 million in 2025, then decreased by 1.97% to $295.3 million in 2026.
• Business Quant data shows COGT's Total Liabilities at $295.3 million in Q1 2026, $301.2 million in Q4 2025, and $123.5 million in Q3 2025.